Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amlodipine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 3/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 2/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 2/20 | 1.00 |
| ▸ | KCNK2 | O95069 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amlodipine SCHEMBL912531 | 1.00 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Levamlodipine SCHEMBL30994756 | 1.00 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Amlodipine SCHEMBL7174865 | 1.00 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Amlodipine SCHEMBL29397019 | 1.00 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Amlodipine SCHEMBL1816641 | 1.00 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Levamlodipine SCHEMBL41283 | 1.00 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| SCHEMBL13097922 | 1.00 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Amlodipine SCHEMBL29664887 | 1.00 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| SCHEMBL29599419 | 1.00 | TBXA2R (1.00) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 | |
| Amlodipine SCHEMBL6666635 | 0.99 | TBXA2R (0.98) | TBXA2RADRA1ASLC6A3ADORA3ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 46379 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-122075488-A | Compound preparation for treating hypertension and preparation method thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-122072268-A | Method for optimizing dissolution curve of tablet and in-vivo bioequivalence | 北京阳光诺和药物研究股份有限公司 | 2026-05-22 | — | — | CN | claimed |
| WO-2026107071-A1 | COMBINATION THERAPY | Retension Pharmaceuticals, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| US-12629363-B2 | Prophylaxis and treatment of angioedema | PHARVARIS GMBH (CH) | 2026-05-19 | — | — | US | claimed |
| US-20260130866-A1 | IMMEDIATE RELEASE AMLODIPINE UBIQUINONE COMPOSITION FOR ENHANCED IMMUNOMODULATORY ACTIVITY | KHAN ABIDA (SA) | 2026-05-14 | — | — | US | claimed |
| EP-4741492-A2 | NECROSIS INHIBITOR | Linkgevity Limited (GB) | 2026-05-13 | — | — | EP | claimed |
| EP-4740962-A1 | PHARMACEUTICAL COMPOSITION, FORMULATION CONTAINING PHARMACEUTICAL COMPOSITION, KIT CONTAINING PHARMACEUTICAL COMPOSITION, PREPARATION METHOD FOR PHARMACEUTICAL COMPOSITION, AND USE OF PHARMACEUTICAL COMPOSITION | Shanghai WD Pharmaceutical Co., Ltd (CN) | 2026-05-13 | — | — | EP | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-0244944-B1 | SALTS OF AMLODIPINE | Pfizer Limited (GB) | 1990-01-24 | — | — | EP | claimed |
| US-4879303-A | BESYLATE SALT OF AMLODIPINE; ANTIISCHEMIC, HYPOTENSIVE | PFIZER INC. (US) | 1989-11-07 | — | — | US | claimed |
| EP-0331382-A2 | Transdermal flux enhancing compositions | PFIZER INC. (US) | 1989-09-06 | — | — | EP | claimed |
| EP-0331315-A2 | Preparation of R- and S-amlodipine | Pfizer Limited (GB) | 1989-09-06 | — | — | EP | claimed |
| EP-0301133-A2 | Long acting formulation | SYNTEX (U.S.A.) INC. (US) | 1989-02-01 | — | — | EP | claimed |
| US-4783337-A | Osmotic system comprising plurality of members for dispensing drug | ALZA CORPORATION (US) | 1988-11-08 | — | — | US | claimed |
| EP-0271983-A1 | Transdermal flux enhancing compositions | PFIZER INC. (US) | 1988-06-22 | — | — | EP | claimed |
| CN-87107548-A | Strengthen the compositions of transdermal flux | — | 1988-05-11 | — | — | CN | claimed |
| EP-0244944-A2 | Salts of amlodipine | Pfizer Limited (GB) | 1987-11-11 | — | — | EP | claimed |
| CN-87102493-A | Improvements in or relating to pharmaceutically acceptable salts | — | 1987-10-14 | — | — | CN | claimed |